Background: Effective, evidence-based
INTRODUCTION
Incretins [glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)] are hormones that stimulate insulin secretion, inhibit glucagon secretion, delay gastric emptying, and decrease appetite [1] .
They also play an important physiological role in regulating both first-and second-phase insulin responses, which are impaired in patients with type 2 diabetes (T2D) [2] . Two classes of incretin-based therapies are currently available: injectable GLP-1 receptor agonists (GLP-1RAs) and oral dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) [3] [4] [5] [6] [7] [8] [9] [10] [11] . The efficacy, tolerability, and clinical use of these agents are described in Tables 1, 2 of GLP-1 activity, and also suppress glucagon release ( Fig. 1) [1, 34, 35] . In contrast, DPP-4 inhibitors prevent enzymatic inactivation of endogenous GLP-1, resulting in prolonged availability of physiological levels of native GLP-1 and GIP and modest receptor activation [1] . Sitagliptin, saxagliptin, and linagliptin are the DPP-4 inhibitors currently available in the United States. A fourth DPP-4 inhibitor, alogliptin, has recently been approved. All are administered orally once daily, with or without food.
Incretin-based therapies target most of the dysfunctional organ systems in T2D, potentially improve b-cell function [18, 22, 36] , have minimal hypoglycemia risk, and are either weight neutral [31] or induce weight loss [15, 29, [37] [38] [39] [40] [41] [42] [43] . However, differences in the mechanisms of action and pharmacodynamics/ pharmacokinetics, between and within these classes, can result in important differences in fasting plasma glucose (FPG), postprandial glucose (PPG), body weight, b-cell function, blood pressure (BP), and safety and tolerability [44] , as found in randomized head-to-head clinical trials (Tables 2, 3 , 4, 5, 6, 7, 8, 9 ). Numerous reviews have examined the efficacy and tolerability of GLP-1RAs and DPP-4 inhibitors based on the results from randomized controlled trials (RCTs) [34, [45] [46] [47] , but few have focused on comparisons among incretin agents. Moreover, in clinical practice, the appropriate choice of incretin therapy for a given patient is not always clear. Rates of minor hypoglycemia after switch to liraglutide; no episodes of major hypoglycemia were reported Table 4 Glycemic effects of GLP-1RAs plus insulin in randomized clinical trials conducted in patients with T2D
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ROLE OF INCRETIN THERAPIES IN DIABETES MANAGEMENT

NEWLY DIAGNOSED, TREATMENT-NAIVE PATIENTS
Recommendations for the initial use of metformin in newly diagnosed patients are nearly universal, unless it is contraindicated. However, some patients with high hemoglobin [19, 54, 55] . Comparative data on the relative impact of incretin therapies among patients inadequately controlled on metformin will be considered later in the manuscript.
Clinical Experience with Incretins as Initial Therapy
In newly diagnosed patients requiring more than metformin to get to their individualized A1C goal, the choice for incretin therapy depends on several factors, including baseline A1C, body mass index, and comorbidities. GLP-1RA plus metformin for obese patients with high A1C typically works well. It is possible to achieve glycemic targets in patients at A1C 10% with GLP-1RAs and metformin [22] . In addition, the sustained weight loss associated with GLP-1RAs in clinical trials-which can be impressive in some patients-is beneficial to many organ systems [26] . Because of the limited glucose-lowering potential of DPP-4 inhibitors, metformin with a DPP-4 inhibitor in patients with baseline A1C C10% will not get most patients to their goal. Although there is evidence suggesting that DPP-4 inhibitors are less effective in patients with A1C \8% [56] , DPP-4 inhibitors can be used in patients with lower A1C when they are of normal weight, particularly when they resist injections.
For patients with high A1C, symptoms of hyperglycemia, and significant glucotoxicity, the use of insulin is recommended in current treatment guidelines. In the author's clinical experience, patients can be weaned off insulin, as glucotoxicity abates, and initiated on metformin and a GLP-1RA. While clinical data on this approach are limited, it has been successful in the author's practice.
INCRETIN AGENTS AS MONOTHERAPY
There are some newly diagnosed patients in whom metformin is inappropriate or contraindicated. Incretin-based therapies may be a useful option in this population, which includes patients with moderate-to-severe renal impairment or heart failure.
However, patients with severe renal impairment or end-stage renal disease (ESRD) may also be poor candidates for some incretin therapies. Because they are cleared through the kidney, exenatide BID and EQW should not be used in this population [5, 7] . Although liraglutide is not cleared by renal mechanisms and no differences in safety and efficacy were found in patients with mild renal impairment in a meta-analysis of the Liraglutide Effect and Action in Diabetes (LEAD) clinical trial program [57] , caution and careful monitoring should still be used when initiating liraglutide in such patients [7] . Sitagliptin, saxagliptin, and alogliptin, but not linagliptin, require dose Linagliptin or reduced-dose sitagliptin or saxagliptin is each a useful option in nonobese patients and/or if a patient with renal insufficiency requires B1% A1C reduction [60] .
DPP-4 inhibitors may be particularly appropriate as initial therapy in frail or slim elderly patients with renal impairment, moderately elevated A1C, and elevated PPG without a substantially elevated FPG [60] .
Incretins, including GLP-1RAs, are also useful in patients who cannot tolerate the gastrointestinal (GI) side effects of metformin.
In the author's experience, GI symptoms with GLP-1RAs are self-limiting and disappear over time, unlike the GI symptoms often observed with metformin. In elderly patients with severe anorexia with metformin monotherapy, monotherapy with a DPP-4 inhibitor is an important option.
Sulfonylureas may also be an option for patients who refuse incretin therapy, but their potential adverse effects on b-cells [61] , elevated risk of hypoglycemia, tendency toward weight gain [3, 4], and limited effectiveness over time should be considered carefully [62] . Compared with sulfonylureas, monotherapy studies with incretin-based therapies demonstrate better safety, and in the case of GLP-1RAs, better efficacy [63, 64] .
Similarly, the author tends to choose incretins over thiazolidinediones (TZDs) in many patients because of the potential adverse effects of TZDs, including weight gain, peripheral edema, and increased risk of congestive heart failure [3].
INCRETINS AS ADD-ON THERAPY
Use of incretins in dual therapy may be considered after lifestyle and drug monotherapy become insufficient and before b-cell function ceases and insulin therapy becomes the only option.
Incretin Plus Metformin Therapy
In head-to-head studies comparing GLP1-RAs with DPP-4 inhibitors, incretin-based therapies have demonstrated modest to robust effects on glycemic indices in patients on metformin, with greater reductions in FPG and A1C with GLP1-RAs, compared with DPP-4 inhibitors. For example, in a head-to-head comparison of EQW with sitagliptin, in which each was used as add-on therapy to metformin, A1C reduction was significantly greater with EQW, overall, as well as among patients with A1C levels C9% [19] . Similarly, in a head-to-head comparison of liraglutide and sitagliptin in patients with inadequate control on metformin, liraglutide was associated with significantly greater reductions in A1C, FPG, and body weight with a similar incidence of hypoglycemia [12, 13] . In both trials, nausea and vomiting were more common with GLP-1RAs than sitagliptin [12, 13, 19] .
Two studies have also compared the efficacy of liraglutide to exenatide BID [22] and EQW [24] in patients inadequately controlled on metformin, sulfonylurea, or both (in the exenatide BID trial) or metformin, sulfonylurea, and/or pioglitazone (in the EQW trial). In the first trial, liraglutide provided significantly greater improvements in A1C (1.1% vs 0.8%, P\0.0001) than EQW [22] .
While both agents were well tolerated, nausea was less persistent and hypoglycemia less frequent with liraglutide than with exenatide BID. When compared with EQW, liraglutide was associated with greater reductions in A1C
(1.48% vs 1.28%) and body weight (3.6 vs 2.7 kg); however, EQW was associated with less nausea and vomiting [24] . Reductions in systolic BP (SBP) were also similar between groups. When the injection barrier is insurmountable, DPP-4 inhibitors can be prescribed; however, patients should be actively involved in the decision-making process. In nonobese patients requiring \1% reduction in A1C, a DPP-4 inhibitor can be used if the patient prefers. However, the author usually switches patients already on DPP-4 inhibitors to GLP-1RAs if they require an additional 0.5% A1C reduction.
Head-to-head clinical trials demonstrate that the more protracted agents have fewer GI symptoms, with exenatide BID causing the most GI symptoms, followed by liraglutide, and then EQW [22, 24, 25] . In the author's experience, many patients who did not tolerate exenatide BID are able to successfully use liraglutide and EQW.
Before initiating any GLP-1RA, patients should be informed of the potential for GI AEs. To mitigate symptoms with exenatide and liraglutide, treatment should be initiated at a lower dose and titrated up to achieve maximal effect. For example, if patients experience nausea with liraglutide, the dose is increased only when the nausea is resolved. In the rare event that nausea remains an issue, the titration of the liraglutide dose can be slowed. This technique has been found to be effective, even though it is not specifically recommended in the labeling [7] . EQW is not usually titrated, but the author's patients with nausea on exenatide BID do not use the 10-mcg dose until the nausea abates.
Incretin Plus Sulfonylurea Therapy
Both sulfonylureas and incretins stimulate release of insulin from pancreatic b-cells [34, 66] . Insulin release by sulfonylureas is glucose independent (primarily affects FPG) and increases the risk for hypoglycemia.
Conversely, incretins stimulate insulin in a glucose-dependent manner, minimizing risk of hypoglycemia. Therefore, combining incretin therapy with a sulfonylurea potentially allows for lowering of the sulfonylurea dose and a possible reduction in the risk of hypoglycemia, while maintaining or increasing glycemic control [5] [6] [7] 67] . While results from clinical trials indicate that adding an incretin to a sulfonylurea reduces A1C by 0.5-1.1% [64, 67, 68] , there are few data on the comparative impact of incretin agents in patients inadequately controlled on sulfonylureas alone.
In patients already using sulfonylureas who need an A1C reduction of 1-1.5%, the dose of sulfonylurea should be reduced when DPP-4 inhibitors or GLP-1RAs are added. However, the current sulfonylurea dose should be maintained if an A1C reduction of [1.5% is needed. The author also asks patients receiving sulfonylurea therapy in combination with an incretin for an extra fingerstick glucose measurement before dinner.
USE OF INCRETINS IN TRIPLE THERAPY
While guidelines often recommend insulin therapy as the preferred option for patients inadequately controlled on metformin and an additional agent, many patients receive triple therapy at this stage, particularly if they are reluctant to initiate insulin.
Incretin Plus Metformin and Sulfonylurea
Although several studies have evaluated the use of incretin therapy in combination with metformin and a sulfonylurea, there have been no such head-to-head comparisons. In one study, liraglutide added to metformin and a sulfonylurea reduced A1C by 1.3% and decreased weight by 1.8 kg [69] . A similar study of exenatide BID reported a reduction in A1C of 1.0% and a weight loss of 2.5% [70] . In these trials, hypoglycemia was reported by 27% [69] of patients on liraglutide and 27% of patients on exenatide [70] . In a study evaluating sitagliptin in combination with metformin and a sulfonylurea, the combination reduced A1C by 0.9% but increased weight by 0.8 kg [71] . The incidence of hypoglycemia with the sitagliptin combination was 16.4%.
The combination of metformin, sulfonylurea, and a GLP-1RA is the author's preferred noninsulin-based triple therapy, because this combination is effective in reducing A1C and FPG with few hypoglycemic events. To avoid hypoglycemia when using this combination, the sulfonylurea dose typically should be reduced when adding an incretin therapy.
Incretin Plus Metformin and TZD Therapy
Adding GLP-1RA to TZD therapy for patients inadequately controlled with TZD and metformin leads to complementary effects: an increase in b-cell insulin secretory function (GLP-1RAs), inhibition of glucose production by the liver (metformin), and an increase in glucose uptake by muscle (TZD), and consequently, improved glycemic control [72] .
Combining incretins with TZDs may also mitigate the adverse effect of TZDs on weight.
Data on the comparative use of incretin therapies with TZDs and metformin are limited. However, a study of liraglutide with metformin and a TZD reported a reduction in A1C of 1.5% with a reduction in weight of 1-2 kg and an incidence of hypoglycemia of 7.9-9.0% [73] . [75] [76] [77] . The author has had no experience with pancreatitis in patients using incretin therapy. Moreover, experts convened by the National Institute of Diabetes and Digestive and Kidney Diseases in June 2013 concluded that there is likely no increased risk for pancreatic cancer associated with incretin therapies, although longer-term studies are needed [78] .
INCRETIN PLUS INSULIN THERAPY
Thyroid Neoplasm
Based on preclinical data, liraglutide and exenatide BID are absolutely contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2 [6, 7] . Although rare (the author has seen medullary thyroid carcinoma three times in 25 years), the author recommends palpating the patient's thyroid gland to examine for nodules before starting therapy. 
